Aim: To compare candesartan cilexetil and lisinopril in fixed combination with hydrochlorothiazide with respect to antihypertensive efficacy and tolerability. Methods: This was a double-blind (double-dummy), randomised, parallel group comparison in patients with a mean sitting diastolic blood pressure 95-115 mm Hg on prior antihypertensive monotherapy. Treatments were candesartan cilexetil/hydrochlorothiazide 8/12.5 mg once daily (n ‫؍‬ 237) and lisinopril/hydrochlorothiazide 10/12.5 mg once daily (n ‫؍‬ 116) for 26 weeks. The primary efficacy variable was change in trough sitting diastolic blood pressure. Results: Changes in mean sitting diastolic blood pressure did not differ significantly between the groups (mean difference 0.5 mm Hg; 95% confidence interval −1.6, 2.7, P ‫؍‬ 0.20). No significant differences between the groups was found for other haemodynamic vari-
Introduction
Only a small proportion of treated hypertensive patients achieve target levels of blood pressure, 1, 2 partly because available drugs have modest efficacy. 3, 4 Monotherapy with any of the current antihypertensive agents leads to acceptable control in less than 50% of patients. 3 However, appropriate combinations of antihypertensive drugs can result in achievement of target blood pressure in almost 90% of individuals. 5 Drugs in effective antihypertensive combinations have complementary modes of action. Thus combined treatment with a drug which stimulates the renin-angiotensin axis and one which blocks the same pathway results in at least additive effects on blood pressure. 6 Thiazide diuretics activate renin through their natriuretic action which reduces extracellular volume and cardiac output although, in the long term, reverse autoregulation leads to normalisation of extracellular volume and decreased peripheral resistance. 7 These physiological changes are associated with a shift in blood pressure regulation to the renin-angiotensin system. At low doses, antihypertensive efficacy is maintained while adverse metabolic effects are minimised. 8 The renin-angiotensin system can be blocked at the stage of angiotensin II generation by inhibition of angiotensin-converting enzyme (ACE). 9 This approach is highly successful but non-specific actions can lead to unwanted effects such as cough and angioedema. 10, 11 The recently introduced selective type I angiotensin II receptor blockers offer a more specific approach to blockade of the reninangiotensin system by antagonising the action of the primary effector molecule, angiotensin II, at the AT 1 receptor, which mediates all the adverse cardiovascular effects of this hormone. [12] [13] [14] [15] Candesartan is a new, potent, angiotensin II type I selective receptor blocker with tight binding to and slow dissociation from the receptor. 13, [16] [17] [18] Candesartan cilexetil is the orally administered pro-drug which is hydrolysed during gastrointestinal absorption into the active molecule, candesartan. 13, 16, 18, 19 Although mainly eliminated unchanged, a small proportion is in turn broken down to an inactive metabolite. 20 Lisinopril is an established long-acting ACE inhibitor which does not require metabolism for action. 21 The objective of this study was to compare the antihypertensive efficacy and tolerability of candesartan cilexetil and those of lisinopril each in combination with low dose hydrochlorothiazide (HCTZ) in hypertensive patients with blood pressure inadequately controlled by existing antihypertensive monotherapy. Fixed combination therapy should improve patient compliance and the lisinopril combination is in routine clinical use. Both candesartan cilexetil and lisinopril have shallow dose-antihypertensive response relationships. 21, 22 In hypertensive subjects, blood pressure reductions after candesartan cilexetil and lisinopril are incremental across the dose ranges 1-16 mg daily and 5-40 mg daily, respectively. However, the bulk of the effects are seen after candesartan cilexetil 8 mg and lisinopril 10 mg daily. In this study each drug was used at submaximal doses and added efficacy obtained by the combination with hydrochlorothiazide.
Subjects and methods

Subjects
Patients aged 20-80 years with primary hypertension were eligible for inclusion if sitting diastolic blood pressure was 95-115 mm Hg on two occasions 1-2 weeks apart 24 h after dosing with antihypertensive monotherapy. Subjects gave written consent for participation after full verbal and written information about the protocol and its risks. Exclusion criteria included women of child-bearing potential, recent significant cardiovascular events or conditions, concomitant drugs with blood pressure modulating effects, contraindications to any of the study drugs, severe concomitant disease or conditions associated with poor compliance.
Design
This was a double-blind (double dummy), randomised, parallel group, multicentre study. Patients who satisfied the inclusion criteria had prior antihypertensive monotherapy withdrawn and were randomised without an intervening drug-free period to combination therapy with candesartan cilexetil and HCTZ 8/12.5 mg or lisinopril and HCTZ 10/12.5 mg, each given once daily for 26 weeks. Patients were seen at 2, 6, 12, 19 and 26 weeks after randomisation. If mean sitting diastolic blood pressure exceeded 100 mm Hg and/or mean sitting systolic blood pressure exceeded 180 mm Hg at any visit after randomisation, the patient was seen again within 2-4 weeks and if blood pressure remained above these limits, the patient was withdrawn from the study. The protocol was approved by the local medical ethics committee at each participating centre.
Treatments
The patients received one of the following treatments once daily in the morning for a minimum of 26 weeks or a maximum of 30 weeks: Fixed combination tablets containing lisinopril 10 mg and HCTZ 12.5 mg were presented in hard gelatine capsules without further manipulation of the marketed formulation. The lisinopril plus HCTZ capsules satisfied US Pharmacopea (USP) criteria for in vitro dissolution. Candesartan cilexetil 8 mg daily has an antihypertensive effect not significantly different from that of enalapril 10 mg daily 23 and therefore would be expected to be equivalent to lisinopril 10 mg daily. 21 Randomisation was performed by computer in blocks of three consecutive patient numbers irrespective of centre or country. Each patient was allocated at random to one of the two treatment regimens in the proportion 2:1 (candesartan cilexetil/HCTZ: lisinopril/HCTZ).
Patients were instructed to return all unused study medication at each study visit. Returned tablets were counted to assess compliance. The criteria for acceptable compliance during the double-blind study period was predetermined as an intake of at least 75% and no more than 110% of drugs.
Study variables
Blood pressure and heart rate was measured at each visit in the morning, immediately before drug administration, 24 h ± 2 (trough) after the previous dose. Measurements were made using a fully automated device (Omron HEM-705CP). 24 At the first visit sitting blood pressure was measured in both arms and the arm with the higher diastolic pressure was used for all subsequent measurements. Sitting blood pressure and heart rate were recorded three times, at least 2 min apart, after the patient had rested in a quiet room for at least 5 min. One measurement of blood pressure and heart rate was made after at least 1 min standing. The values used in the statistical analysis were the means of triplicate and single readings. For each patient, every attempt was made to ensure that all blood pressure measurements were performed by the same individual. If the Omron device failed, the instrument usually used at the clinic was used for all blood pressure measurements in that individual.
Adverse reactions reported spontaneously and in response to a non-leading question were recorded at each visit. The criteria for judgment of severity and intensity of adverse events were defined a priori. Resting ECG, physical and laboratory examinations were performed at fixed intervals during the study. Values judged by the investigator as clinically relevant deteriorations from baseline were defined as adverse events. All adverse events presenting when the patient completed or discontinued the study were followed for 2-4 weeks.
Statistics
The primary variable was the change in sitting diastolic blood pressure from baseline to 26 weeks of treatment. This variable and all other haemodynamic variables were tested by analysis of covariance (ANCOVA) with baseline values as covariates The true mean difference between the candesartan cilexetil/HCTZ and the lisinopril/HCTZ group, and the corresponding two-sided 95% confidence interval were estimated. A P-value of Ͻ0.05 was taken as statistically significant.
Two analyses were performed for haemodynamic variables. An intention-to-treat (ITT) analysis included all patients who took at least one dose of double-blind medication and who had efficacy data available after randomisation. The ITT population was analysed using the last value carries forward (LVCF) method. For patients who did not complete the study (or who had missing data at the last visit), the last available data point after randomisation was used as the week 26 (LVCF) value. The per protocol (PP) analysis included only those patients in the ITT population who met all of the inclusion criteria, and did not meet any of the exclusion criteria or any of the pre-defined study violation criteria.
The Mantel-Haenzel test, stratified for centre, was used to analyse the proportion of responders (sitting diastolic blood pressure 90 mm Hg or less and/or reduction of sitting diastolic blood pressure from baseline by at least 10 mm Hg) and the proportion of patients with controlled diastolic blood pressure (sitting diastolic blood pressure 90 mm Hg or less) after 26 weeks, and tolerability defined as the number of patients with at least one adverse event. Multiple episodes of the same adverse event were counted only once. Laboratory variables were analysed by the same model used for haemodynamic variables or by non-parametric methods as appropriate. Tolerability and laboratory analyses were based on the safety population, patients who took at least one dose of double-blind study medication and provided post-dose data.
Determination of sample size
Based on the results of previous studies, a residual standard deviation of 7.5 mm Hg was expected; with 70 patients in each group, the study was expected to
Journal of Human Hypertension have a power of 88% to detect a true mean treatment difference in efficacy of 4 mm Hg. In order to maximise experience with candesartan cilexetil/HCTZ, it was planned to randomise an extra 70 patients to this group. The actual residual standard duration was higher than expected (8.0 mm Hg) but as the numbers of patients in the groups were 238 (candesartan cilexetil/HCTZ) and 117 (lisinopril/ HCTZ), power was maintained.
Results
Patient characteristics
In total, 418 patients from Finland, Norway, The Netherlands and the United Kingdom were enrolled in the study. Of these, 355 were randomised. The ITT population consisted of 237 patients randomised to candesartan cilexetil/HCTZ and 116 to lisinopril/HCTZ. The numbers of patients who completed the double-blind period were 190 and 96, respectively.
Demographic and other baseline characteristics of the ITT population are shown in Table 1 . The groups were similar with respect to these variables and also race, height, body mass index, medical history, duration of hypertension and WHO stage. All but five patients were Caucasian.
Blood pressure and heart rate in the ITT population at 26 weeks are shown in Table 2 and sitting blood pressures 24 h post dose for each treatment group during the randomised treatment period are illustrated in Figure 1 . Individual data for sitting diastolic blood pressure at 26 weeks are shown in Figure 2 . Differences between treatments are presented in Table 3 . 
Sitting blood pressure and heart rate
The adjusted mean changes from baseline to week 26 (LVCF) in sitting diastolic blood pressure, the primary variable, were 9.8 mm Hg (95% confidence interval 8.6, 11.0) and 10.3 mm Hg (8.5, 12.2) after candesartan cilexetil/HCTZ and lisinopril/HCTZ respectively. The adjusted mean difference between the treatments was 0.5 mm Hg (−1.6, 2.7, P = 0.20). Changes in individuals are shown in Figure 3 . Both treatments reduced sitting diastolic blood pressure with no significant difference between the groups. Mean sitting systolic blood pressure also decreased over the treatment period in both groups. In the candesartan cilexetil/HCTZ group, the adjusted mean reduction was 16.2 mm Hg (13.9, 18.6) while in the lisinopril/HCTZ group the adjusted mean change was 18.4 mm Hg (14.8, 21.9). There was no statistically significant difference between the groups (adjusted mean difference 2.1 mm Hg, 95% CI −2.1, 6.4; P Ͼ 0.200). There was a slight, but statistically significant, increase in sitting heart rate from baseline to 26 weeks in the candesartan cilexetil/HCTZ group (1.8 bpm, 95% CI 0.4, 3.3). In the lisinopril/HCTZ group, heart rate was little changed (−0.2 bpm, 95% CI −2.4, 2.0). The difference between the groups (2.0, 95% CI −0.6, 4.6) was not statistically significant (P = 0.133).
Standing blood pressure and heart rate
The pattern of changes in standing blood pressure from baseline to week 26 was similar to that in the sitting position without indication of an orthostatic effect. Standing systolic blood pressure fell by 16.0 mm Hg (13.3, 18.7) in the candesartan cilexetil/ HCTZ group and 20.5 mm Hg (16.3, 24.6) in the lisinopril/HCTZ group; the difference between groups (4.5 mm Hg, 95% CI −0.5, 9.4) was not significant (P = 0.076). The corresponding changes in standing diastolic blood pressure were 7.8 mm Hg (6.2, 9.3) and 8.0 (5.7, 10.4) in the candesartan cilexetil/HCTZ and lisinopril/HCTZ groups, respectively, the adjusted mean difference (0.2 mm Hg, 95% CI −2.6, 3.1) was not significant (P Ͼ 0.200). Heart rate was again significantly increased in the candesartan cilexetil/HCTZ group in the standing position (2.7 bpm, 95% CI 0.9, 4.5) but a similar increase in the lisinopril/HCTZ group (2.7 bpm, 95% CI −0.2, 5.3) did not achieve statistical significance; the difference in heart rate between the groups (0.1 bpm, 95% CI −3.2, 3.4) was not significant (P Ͼ 0.200).
Response rates
The proportion of patients responding to the treatment regimens are shown in Table 4 . As defined by a mean sitting diastolic blood pressure р90 mm Hg or a reduction of mean sitting diastolic blood pressure from baseline to week 26 (LVCF) у10 mm Hg, the estimated proportions of responders were 54.4% (95% CI 48.1, 60.8) and 62.1% (95% CI 53.2, 70.9) in the candesartan cilexetil/HCTZ and lisinopril/HCTZ groups respectively. The difference in proportion of responders between the two groups was not statistically significant (P = 0.094). The proportion of patients with achieved sitting diastolic blood pressure р90 mm Hg was little different between the groups: 45.1% (95% CI 38.8, 51.5) for candesartan cilexetil/HCTZ and 44.8% (95% CI 35.8, 53.9) for lisinopril/HCTZ (P Ͼ 0.200). 
Per protocol analysis
Results for sitting diastolic blood pressure in the PP analysis are presented in Table 5 . These findings confirm the lack of differences between the groups in the ITT analysis. The reduction from baseline to 26 weeks in the candesartan cilexetil/HCTZ group was 12.0 mm Hg (95% CI 10.7, 13.3) and in the lisinopril/HCTZ group 11.0 mm Hg (95% CI 8. 
Tolerability
During the run-in period, adverse events were reported in 25 patients (10.5%) of the 238 patients later randomised to candesartan cilexetil/HCTZ and in 16 of 117 patients (13.7%) later randomised to lisinopril/HCTZ. Patients with adverse events during randomised therapy are shown in Table 6 . Adverse events occurring in at least 4% of patients in each treatment group are listed in Table 7 .
The proportion of patients with at least one adverse event was significantly lower in the candesartan cilexetil/HCTZ group compared with the lisinopril/HCTZ group (68.9% vs 79.5%, P = 0.020). Withdrawal due to adverse events was also less common in the candesartan cilexetil group (5.9% vs a AEs for which physician causality rating was possible or probable relationship to study drug. 12.0%). The main reason for discontinuation in the lisinopril/HCTZ group was cough which was the most common new adverse reaction with that therapy and much more common than in the candesartan cilexetil group (23.1% vs 4.6%). The most common adverse events reported in the candesartan cilexetil/HCTZ group were dizziness/vertigo and headache (each 11.8%). Two cases of angioedema were reported in the lisinopril/HCTZ group.
Laboratory variables
There were no clinically relevant changes in laboratory or ECG variables. Haemoglobin concentration was reduced slightly but significantly after both treatment regimens (−1.1 g/l and −1.6 g/l after candesartan cilexetil/HCTZ and lisinopril/HCTZ respectively). Likewise, median haematocrit fell by 1% on both treatments. Mean serum uric acid concentration was increased significantly by both treatments: 24.5 mol/l (7.1%) by candesartan cilexetil/HCTZ and 26.9 mol/l (7.6%) by lisinopril/HCTZ. Hyperuricaemia was reported in 1.3% in the candesartan cilexetil/HCTZ group and 2.6% of patients in the lisinopril/HCTZ group. Neither treatment was associated with clinically relevant changes in serum electrolytes. There were not significant differences between the treatment groups.
Compliance
As assessed by tablet count, compliance was good. Overall 90% of patients in the ITT population took 90-110% of the study medication during the double-blind treatment period. The percentage of patients taking 90-110% of study medication was similar in each treatment group.
Discussion
Blood pressure
For the primary efficacy variable, change in sitting diastolic blood pressure over 26 weeks of treatment, responses to the fixed combinations of candesartan cilexetil plus HCTZ 8/12.5 mg daily and lisinopril plus HCTZ 10/12.5 mg daily did not differ significantly in the ITT analysis. Likewise, changes in sitting systolic blood pressure, and in standing systolic and diastolic blood pressure were similar in the two treatment regimens. Blood pressure reductions in the lisinopril group were numerically greater, although differences were not statistically significant. However, the PP analysis failed to confirm the advantage of lisinopril-based treatment. Here, there were trends for greater changes in sitting diastolic blood pressure and response rates in the candesartan cilexetil group. Therefore the two treatments can be considered to have equivalent antihypertensive efficacy. The 95% confidence intervals indicate that it is unlikely that the two treatments differ in efficacy by 4 mm Hg or more in diastolic blood pressure.
Heart rate
In the sitting and standing posture, heart rate was increased slightly but significantly in the patients treated with candesartan cilexetil and HCTZ. No significant changes in heart rate were seen in the lisinopril/HCTZ treated patients but there were no significant differences between the treatment groups. Ninety-five percent confidence intervals exclude differences of 5 bpm in heart rate sitting or erect. Such differences in heart rate are unlikely to be of clinical significance.
Tolerability
Both treatment regimens were well tolerated. Compared with lisinopril/HCTZ a significantly lower proportion of patients receiving candesartan cilexetil/HCTZ developed at least one adverse event.
Withdrawal due to adverse events was also less common in the candesartan cilexetil group (6% vs 12%). A much higher proportion of lisinopril/HCTZ treated patients developed cough and discontinued therapy due to this adverse event. The incidence of spontaneously reported cough was Ͼ20% in the lisinopril treated group compared with Ͻ5% in the candesartan cilexetil group. Also, angioedema was reported only in the lisinopril/HCTZ treated patients; angioedema has never been recorded in patients treated with candesartan cilexetil. Cough and angioedema are well-recognised class-specific complications of all ACE inhibitors. 10, 11 The suggested mechanism reflects the lack of specificity of ACE which is also known as kininase II, the enzyme responsible for degradation of various other vasoactive peptides. 10 Thus, ACE inhibitors not only reduces concentration of angiotensin II but also results in accumulation of bradykinin, substance P and other inflammatory substances thought to be involved in these adverse reactions. The high specificity of angiotensin II antagonists for the reninangiotensin system means that these drugs would not be expected to give rise to cough or angioedema. 12, 14, 15 The results of this study confirm the distinction between ACE inhibitors (lisinopril) and angiotensin II antagonists (candesartan cilexetil) in side effect profile.
Laboratory variables
There were no clinically relevant changes in laboratory variables with either treatment. The small reductions in haematological indices may reflect blockade of a stimulant effect of the renin-angiotensin system on erythropoetin production. 25 Such effects have previously been reported with ACE inhibitors 25, 26 and angiotensin II antagonists. [27] [28] [29] The increase in serum uric acid seen in both treatment groups probably reflects the known influence of thiazide diuretics. 7, 8 Among angiotensin II antagonists, only losartan has been shown to affect uric acid metabolism.
12-14 ACE inhibitors have no known effect on serum uric acid. 21 Hyperuricaemia was rare with both treatments.
Conclusions
This study demonstrates that the combination of candesartan cilexetil and hydrochlorothiazide 8/12.5 mg daily has similar antihypertensive effects on those with lisinopril and hydrochlorothiazide 10/12.5 mg daily. However, the candesartan cilexetil/hydrochlorothiazide combination was better tolerated than the lisinopril/hydrochlorothiazide fixed combination.
